Srdan Verstovsek MD, PhD

Dr. Verstovsek is the United Energy Resources, Inc., Professor of Medicine and hematologist-oncologist at MD Anderson. Dr. Verstovsek is a global leader in myeloproliferative neoplasms (MPN) and the Founder/Director of the largest MPN Clinical Research Center worldwide. 

<br/><br/>

Dr. Verstovsek has achieved international acclaim for his leadership in developing landmark MPN therapeutics. He led more than 60 early/advanced phase clinical trials of novel MPN drugs, including ruxolitinib, the only FDA-approved medication for myelofibrosis (MF) until 2019, and second-line treatment for polycythemia vera. He is leading several pivotal phases 3 trials for promising MPN medications. He has published 24 book chapters, and more than 600 peer-reviewed original articles/reviews in leading medical journals, such as the New England Journal of Medicine, Blood, Leukemia, and Lancet. 

<br/><br/>

Dr. Verstovsek is the lead and senior author of over 80 and 200 articles, respectively (h-index 91). He received several awards, including the Distinguished Clinical Faculty Mentoring Award (2021), the Waun Ki Hong Faculty Award for Excellence in Team Science (2021), the Otis & Pearl Walters Faculty Achievement Award in Clinical Research (2017), the Seventh Annual Irwin H. Krakoff Award for Excellence in Clinical Research (2013), and the Celgene Young Investigator Award (2010). 

<br/><br/>

Dr. Verstovsek was elected a member of the American Society for Clinical Investigation in 2015. His contributions have been globally recognized with numerous invitations as expert speaker/educator/Chair at the most significant national/international conferences. He regularly engages at multiple levels with MPN patients’ advocacy groups/societies. He is a Co-Founder/Executive Committee Member of the International Working Group for MF Treatment and Research.